What does Telix Pharmaceuticals (Belgium) do?

Telix Pharmaceuticals (Belgium) is registered with the CBE as active in: Vervaardiging van overige farmaceutische producten. Private Limited, started on 9 May 2018, 1 establishment.

What is the address of Telix Pharmaceuticals (Belgium)?

The registered office of Telix Pharmaceuticals (Belgium) is located at Rue Jules Bordet 55, 7180 Seneffe.

Is Telix Pharmaceuticals (Belgium) still active?

Yes. According to the CBE (29 October 2026) Telix Pharmaceuticals (Belgium) is active, legal situation “Normale toestand”, started on 9 May 2018.

Is Telix Pharmaceuticals (Belgium) registered on Peppol?

Yes, Telix Pharmaceuticals (Belgium) is registered on the Peppol network with ID 0208:0695832765.

What is the enterprise number of Telix Pharmaceuticals (Belgium)?

The enterprise number of Telix Pharmaceuticals (Belgium) is BE0695832765.

When was Telix Pharmaceuticals (Belgium) founded?

Telix Pharmaceuticals (Belgium) was founded on 9 May 2018.

Who are the directors of Telix Pharmaceuticals (Belgium)?

According to the 2025 annual accounts, the directors of Telix Pharmaceuticals (Belgium) are: Caroline Defraiteur, Ortiz Raphael.

Is Telix Pharmaceuticals (Belgium) a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 9 May 2018; 4 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did Telix Pharmaceuticals (Belgium) make in 2025?

Telix Pharmaceuticals (Belgium) recorded a loss after taxes of € 54,903 in financial year 2025.

What is the revenue of Telix Pharmaceuticals (Belgium)?

In its most recent annual accounts (2025), Telix Pharmaceuticals (Belgium) reported revenue of € 14,873,793.

How much does an employee at Telix Pharmaceuticals (Belgium) earn?

The average wage cost per full-time employee at Telix Pharmaceuticals (Belgium) was € 155,200 in 2025: staff costs of € 7.9 million for 51 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Telix Pharmaceuticals (Belgium) have?

According to the 2025 annual accounts, Telix Pharmaceuticals (Belgium) has 51 full-time equivalents (FTE).

Telix Pharmaceuticals (Belgium) (Private Limited)

Dossier Telix Pharmaceuticals (Belgium), printed on 29 October 2026 from databakkes.be/en/0695832765/telix-pharmaceuticals-belgium. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Board fully replaced NBB

No director from three years ago is still active according to annual account 2025.

Financials

Financial year 2025

Telix Pharmaceuticals (Belgium) from Seneffe, company number BE0695832765, closed financial year 2025 with a result of € -54,903 after tax. For that financial year Telix Pharmaceuticals (Belgium) recorded revenue of € 14.9 million and equity of € 515,466. Compared with financial year 2024, the result moved from € 30,074 to € -54,903. The company made a loss. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 31, 2026.

What it is worth Healthy

€ 515,466

▼ 10% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -54,903

▼ still € 30,074 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 1.9 million

▲ 282% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 151,647.

People and assets in 2025

Full-time equivalents

▲ 16.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 6.9 million in 2025, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 7.9 million

▲ 89% vs 2024

€ 155,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 694,535

▲ € 676,893 vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 14.8 million

▼ 2% vs 2024

€ 7.2 million is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 2.6 million

▲ 19% vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 129 days on average.

Taxes and wages

€ 2.7 million

▲ 132% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2021	2023	2024	2025	Change 2024 → 2025
Revenue	-	-	€ 8,629,300 Revenue 2024: € 8,629,300 First fiscal year in the series	€ 14,873,793 Revenue 2025: € 14,873,793 ▲ 72% vs 2024 (€ 8,629,300) Favourable step	▲ 72%
Gross margin	€ -2,195,019 Gross margin 2021: € -2,195,019 First fiscal year in the series	€ 3,023,129 Gross margin 2023: € 3,023,129 ▲ € 5.2 million vs 2021 (€ -2,195,019) Favourable step	-	-
Profit after taxes	€ 64,209 Profit after taxes 2021: € 64,209 First fiscal year in the series	€ -1,008 Profit after taxes 2023: € -1,008 ▼ € 65,217 vs 2021 (€ 64,209) Unfavourable step	€ 30,074 Profit after taxes 2024: € 30,074 ▲ € 31,082 vs 2023 (€ -1,008) Favourable step	€ -54,903 Profit after taxes 2025: € -54,903 ▼ € 84,977 vs 2024 (€ 30,074) Unfavourable step	▼ € 84,977
Equity	€ 151,865 Equity 2021: € 151,865 First fiscal year in the series	€ 540,295 Equity 2023: € 540,295 ▲ 256% vs 2021 (€ 151,865) Favourable step	€ 570,369 Equity 2024: € 570,369 ▲ 6% vs 2023 (€ 540,295) Favourable step	€ 515,466 Equity 2025: € 515,466 ▼ 10% vs 2024 (€ 570,369) Unfavourable step	▼ 10%
Total debts	€ 3,487,354 Total debts 2021: € 3,487,354 First fiscal year in the series	€ 17,688,512 Total debts 2023: € 17,688,512 ▲ € 14.2 million vs 2021 (€ 3,487,354) Unfavourable step	€ 39,988,699 Total debts 2024: € 39,988,699 ▲ 126% vs 2023 (€ 17,688,512) Unfavourable step	€ 49,672,715 Total debts 2025: € 49,672,715 ▲ 24% vs 2024 (€ 39,988,699) Unfavourable step	▲ 24%
Cash	€ 27,472 Cash 2021: € 27,472 First fiscal year in the series	€ 2,636,610 Cash 2023: € 2,636,610 ▲ € 2.6 million vs 2021 (€ 27,472) Favourable step	€ 497,986 Cash 2024: € 497,986 ▼ 81% vs 2023 (€ 2,636,610) Unfavourable step	€ 1,900,383 Cash 2025: € 1,900,383 ▲ 282% vs 2024 (€ 497,986) Favourable step	▲ 282%
Land & buildings	€ 1 Land & buildings 2021: € 1 First fiscal year in the series	€ 1 Land & buildings 2023: € 1 Unchanged (€ 1) Unchanged	€ 1 Land & buildings 2024: € 1 Unchanged (€ 1) Unchanged	€ 13,295,668 Land & buildings 2025: € 13,295,668 ▲ € 13.3 million vs 2024 (€ 1) Unchanged	▲ € 13.3 million
Retained profit	€ 139,465 Retained profit 2021: € 139,465 First fiscal year in the series	€ 176,477 Retained profit 2023: € 176,477 ▲ 27% vs 2021 (€ 139,465) Favourable step	€ 206,551 Retained profit 2024: € 206,551 ▲ 17% vs 2023 (€ 176,477) Favourable step	€ 151,647 Retained profit 2025: € 151,647 ▼ 27% vs 2024 (€ 206,551) Unfavourable step	▼ 27%
Bank debt	€ 0 Bank debt 2021: € 0 First fiscal year in the series	€ 5,940,797 Bank debt 2023: € 5,940,797 Unchanged (€ 0) Unfavourable step	€ 15,100,669 Bank debt 2024: € 15,100,669 ▲ 154% vs 2023 (€ 5,940,797) Unfavourable step	€ 14,794,379 Bank debt 2025: € 14,794,379 ▼ 2% vs 2024 (€ 15,100,669) Favourable step	▼ 2%
Balance sheet total	€ 6,866,639 Balance sheet total 2021: € 6,866,639 First fiscal year in the series	€ 21,870,887 Balance sheet total 2023: € 21,870,887 ▲ 219% vs 2021 (€ 6,866,639) Unchanged	€ 47,477,228 Balance sheet total 2024: € 47,477,228 ▲ 117% vs 2023 (€ 21,870,887) Unchanged	€ 57,106,341 Balance sheet total 2025: € 57,106,341 ▲ 20% vs 2024 (€ 47,477,228) Unchanged	▲ 20%
Employees (FTE)	1.7 Employees (FTE) 2021: 1.7 First fiscal year in the series	25.2 Employees (FTE) 2023: 25.2 ▲ 23.5 vs 2021 (1.7) Unchanged	34.9 Employees (FTE) 2024: 34.9 ▲ 9.7 vs 2023 (25.2) Unchanged	51 Employees (FTE) 2025: 51 ▲ 16.1 vs 2024 (34.9) Unchanged	▲ 16.1

Key figures of Telix Pharmaceuticals (Belgium), fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Telix Pharmaceuticals (Belgium)?

What happened at Telix Pharmaceuticals (Belgium) in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2029 Ortiz Raphael stepped down as director. NBB
Jul 31, 2026 New annual accounts for financial year 2025: loss of € 54,903 (▼ € 84,977 vs 2024). Source: NBB ↗
2025 Caroline Defraiteur became a director. NBB
2023 Ortiz Raphael became a director. NBB
May 9, 2018 New establishment in Seneffe. KBO
May 9, 2018 Start of the company according to the CBE. KBO

In short

From € 64,209 profit in 2021 to € 54,903 loss in 2025.

Paid € 339,658 in corporate taxes since 2021.

Best year ever: 2021, with € 64,209 profit.

On average € 120,000 of value added per employee in 2023.

Original PDFs at the National Bank ↗

Management

Telix International Pty Ltd Autre 100%

Telix Pharmaceuticals (Belgium)

Behind Telix Pharmaceuticals (Belgium) is Caroline Defraiteur. The shares are held by Telix International Pty Ltd Autre (100%).

Directors

According to the 2025 annual accounts

Caroline Defraiteur

Director

since 2025

Ortiz Raphael

Director

since 2023 · until 2029

Shareholders

Telix International Pty Ltd Autre

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Jules Bordet 55

7180 Seneffe

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0695.832.765

VAT number

BE 0695.832.765

Registered office

Rue Jules Bordet 55, 7180 Seneffe

Names & denominations

Telix Pharmaceuticals (Belgium)

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

9 May 2018

Peppol

Active · Active since 1 Jan 2001

Activities · NACE

Vervaardiging van overige farmaceutische producten

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

Vervaardiging van geneesmiddelen

View on CBE Public ↗ Annual accounts (NBB) ↗

Telix Pharmaceuticals (Belgium)

Warning lights

Financials

What happened to Telix Pharmaceuticals (Belgium)?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions